Direkt zum Inhalt
Merck

Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis.

Journal of hepatology (1999-01-06)
R W Ammann, A Fleiner-Hoffmann, F Grimm, J Eckert
ZUSAMMENFASSUNG

Long-term chemotherapy of human alveolar echinococcosis with benzimidazole compounds (mebendazole, albendazole) has been shown to be primarily parasitostatic, but its curative (parasitocidal) efficacy is debated. This article reports on a 67-year-old male patient with non-resectable alveolar echinococcosis of the liver who had been continuously treated for 13 years with mebendazole (approximately 45-48 mg/kg body weight per day) and who was closely monitored according to a specific protocol. At the age of 80 years the patient died of oesophageal variceal bleeding. During treatment the hepatic lesion had decreased markedly in size in association with progression of perifocal calcification. At autopsy, a well-demarcated, necrotic, partially calcified, parasite-induced lesion of the right liver lobe and secondary biliary cirrhosis were found. Remnants of parasite tissue obtained from the periphery of the lesion showed a small-cystic structure, but it was not viable, as evidenced by transplantation of tissue blocks to rodents. The case is suggestive for a parasitocidal efficacy of mebendazole treatment carried out for 13 years, and is discussed in context with conflicting literature data.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Mebendazol, analytical standard, ≥98% (HPLC)
USP
Mebendazol, United States Pharmacopeia (USP) Reference Standard
Mebendazol, European Pharmacopoeia (EP) Reference Standard
Supelco
Mebendazol, VETRANAL®, analytical standard
Mebendazol für die Systemeignung, European Pharmacopoeia (EP) Reference Standard